- Home
- LFST vs ELVN Comparison
LFST vs ELVN Comparison
Compare LFST & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFST | ELVN |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.2B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LFST | ELVN |
|---|---|---|
| Price | $13.83 | $44.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $14.45 | ★ $74.42 |
| AVG Volume (30 Days) | ★ 2.9M | 1.6M |
| Earning Date | 11-05-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,424,285,000.00 | N/A |
| Revenue This Year | $19.96 | N/A |
| Revenue Next Year | $14.48 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 13.85 | N/A |
| 52 Week Low | $5.87 | $14.79 |
| 52 Week High | $14.31 | $62.32 |
Technical Indicators
Market Signals| Indicator | LFST | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 72.29 | 61.80 |
| Support Level | $11.73 | $44.18 |
| Resistance Level | N/A | $47.88 |
| Average True Range (ATR) | 0.49 | 1.84 |
| MACD | 0.14 | 1.04 |
| Stochastic Oscillator | 96.20 | 99.42 |
Price Performance
Historical ComparisonAbout LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.